Zura Bio Ltd
ZURA evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $515.6M
- Lead Asset:
- crebankitug (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ZURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZURA
Zura Bio Ltd (ZURA) is a clinical-stage biotechnology company developing novel bispecific antibodies for autoimmune and inflammatory diseases, with its lead candidate tibulizumab in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis.
Key risk: Phase 2 trial failure risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$515.6M
Cash Runway
—
Lead Asset
crebankitug (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Zura Bio Ltd.
Zura Bio Ltd (ZURA) is a clinical-stage biotechnology company developing novel bispecific antibodies for autoimmune and inflammatory diseases, with its lead candidate tibulizumab in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis.
- Lead drug tibulizumab is a first-in-class bispecific antibody targeting both BAFF and IL-17A, currently in Phase 2 for hidradenitis suppurativa (HS) and systemic sclerosis (SSc) [pipeline].
- Cash and equivalents were $205.1M as of 2026-06-30, with a net loss of -$26.3M for the same period [sec].
- Both Phase 2 studies (TibuSHIELD for HS and a separate SSc trial) completed enrollment ahead of targets, with 247 participants randomized in the HS trial [news · 2026-06-29].
- Tibulizumab is developed under a collaboration with Lilly, which holds exclusive rights to negotiate further development after clinical results, with potential milestone payments up to $155M (development) and $440M (sales) plus royalties [pipeline].
- A preclinical candidate, crebankitug (ZB-168), targets IL-7R alpha chain and is partnered with Pfizer [pipeline].
What works
- Tibulizumab has completed enrollment in two Phase 2 studies ahead of schedule, indicating strong operational execution and patient recruitment [news · 2026-06-29].
- The company has a substantial cash runway, with $205.1M in cash as of 2026-06-30, expected to fund operations into 2028 [sec; news · 2026-03-31].
- Zura Bio has secured high-value partnerships with Lilly and Pfizer, providing non-dilutive funding and validation of its platform [pipeline].
What to weigh
- Net losses are widening, with a net loss of -$26.3M reported for the period ending 2026-06-30, reflecting high R&D spending [sec].
- Tibulizumab faces a competitive landscape including established TNFα, IL-17, and BTK inhibitors in HS and SSc [pipeline].
- The company is pre-revenue and entirely dependent on successful clinical outcomes and partnership milestones for future funding [news · 2026-09-11].
From the filings
Quoted directly from source documents.
Tibulizumab is a bispecific antibody targeting BAFF and IL-17A.
“Bispecific dual-antagonist antibody engineered by the fusion of TALTZ® (ixekizumab) and tabalumab to neutralize interleukin-17A (IL-17A) and B-cell activating factor (BAFF).”
Enrollment completed in HS Phase 2 trial with 247 participants.
“TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS”
News · June 29, 2026
Catalyst timeline
- 2026-12-31 · Phase 2 TibuSHIELD readout in hidradenitis suppurativa — Topline data from the Phase 2 trial of tibulizumab in HS is expected in Q4 2026, which will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- Phase 2 trial failure risk — Tibulizumab's Phase 2 readouts in HS and SSc are pivotal; failure could severely impact valuation and partnership terms [news · 2026-10-07].
- Cash burn rate — With a net loss of $26.3M in a single quarter, the $205.1M cash pile may be consumed faster than anticipated if trials extend [sec].
- Competitive pressure — Tibulizumab competes with approved IL-17 inhibitors and BTK inhibitors, which may limit market uptake even if approved [pipeline].
- Dependence on partnerships — Lilly and Pfizer have significant control over development and commercialization, potentially limiting Zura's strategic flexibility [pipeline].
What to watch
- Topline Phase 2 TibuSHIELD readout in hidradenitis suppurativa expected in Q4 2026 [news · 2026-10-07].
- Phase 2 readout for systemic sclerosis (SSc) expected in 2026-2027 [news · 2026-01-12].
- Lilly's decision on exercising exclusive negotiation rights after clinical results, which could trigger milestone payments [pipeline].
- Cash runway and burn rate updates in upcoming quarterly financial reports [sec].
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run Zura Bio Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zura Bio Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$26M
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
93
Total value held
$394.1M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 9,067,001 | $53.9M |
| venrock adviser, llc | 6,434,990 | $38.3M |
| jpmorgan chase & co | 4,458,851 | $25.3M |
| great point partners llc | 4,215,930 | $25.1M |
| braidwell lp | 3,988,989 | $23.7M |
| siren, l.l.c. | 3,734,866 | $22.2M |
| commodore capital lp | 3,250,000 | $19.3M |
| pfizer inc | 2,838,913 | $16.8M |
| adage capital partners gp, l.l.c. | 2,750,000 | $16.4M |
| affinity asset advisors, llc | 2,564,303 | $15.3M |
Showing top 10 of 93 institutional holders of Zura Bio Ltd. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.9%
- Days to cover
- 11.2
- Shares short
- 6,974,577
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZURA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zura Bio Ltd?
Zura Bio Ltd (ZURA) is a clinical-stage biotechnology company developing novel bispecific antibodies for autoimmune and inflammatory diseases, with its lead candidate tibulizumab in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis.
What is Zura Bio Ltd's lead drug candidate?
Zura Bio Ltd's most advanced tracked candidate is crebankitug (Preclinical) for Autoimmune diseases where IL-7 or TSLP signaling has been implicated.
Who is the CEO of Zura Bio Ltd?
Dr. Sandeep Chidambar Kulkarni M.D. is the chief executive officer of Zura Bio Ltd (ZURA).
Where is Zura Bio Ltd headquartered?
Zura Bio Ltd (ZURA) is headquartered in Henderson, NV, United States.
What therapeutic areas does Zura Bio Ltd focus on?
Zura Bio Ltd develops therapies across Immunology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.